These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. [Therapeutic efficacy of benzoxazinorifamycin KRM-1648 against experimental murine tuberculosis: (1). A study on the efficacy of short course treatment with the intratracheal and intravenous infection model]. Doi N Kekkaku; 1998 Feb; 73(2):53-64. PubMed ID: 9545697 [TBL] [Abstract][Full Text] [Related]
5. In vitro bactericidal and in vivo therapeutic activities of a new rifamycin derivative, KRM-1648, against Mycobacterium tuberculosis. Yamamoto T; Amitani R; Suzuki K; Tanaka E; Murayama T; Kuze F Antimicrob Agents Chemother; 1996 Feb; 40(2):426-8. PubMed ID: 8834891 [TBL] [Abstract][Full Text] [Related]
6. Activity of KRM-1648 alone or in combination with both ethambutol and kanamycin or clarithromycin against Mycobacterium intracellulare infections in beige mice. Yamamoto T; Amitani R; Suzuki K; Tanaka E; Murayama T; Kuze F Antimicrob Agents Chemother; 1996 Feb; 40(2):429-32. PubMed ID: 8834892 [TBL] [Abstract][Full Text] [Related]
7. [In vivo activities of benzoxazinorifamycin KRM-1648, clarithromycin, and levofloxacin, or combination of KRM-1648 with diclofenac sodium against Mycobacterium avium infection induced in mice]. Akaki T; Sato K; Shimizu T; Tomioka H; Kawahara S Kekkaku; 1997 Aug; 72(8):491-7. PubMed ID: 9293712 [TBL] [Abstract][Full Text] [Related]
8. Activity of KRM 1648 alone or in combination with ethambutol or clarithromycin against Mycobacterium avium in beige mouse model of disseminated infection. Bermudez LE; Kolonoski P; Young LS; Inderlied CB Antimicrob Agents Chemother; 1994 Aug; 38(8):1844-8. PubMed ID: 7986018 [TBL] [Abstract][Full Text] [Related]
9. [Studies on therapeutic efficacy of a new anti-tuberculous drug, benzoxazinorifamycin, against murine experimental mycobacterial infections: attempt at various regimens and protocols]. Tomioka H; Saito H Kekkaku; 1994 Nov; 69(11):703-10. PubMed ID: 7837724 [TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo activities of the benzoxazinorifamycin KRM-1648 against Mycobacterium tuberculosis. Hirata T; Saito H; Tomioka H; Sato K; Jidoi J; Hosoe K; Hidaka T Antimicrob Agents Chemother; 1995 Oct; 39(10):2295-303. PubMed ID: 8619585 [TBL] [Abstract][Full Text] [Related]
11. [Therapeutic efficacy of a benzoxazinorifamycin, KRM-1648, administered at the different periods of infection in Mycobacterium intracellulare--infected mice]. Tomioka H; Sato K; Saito H; Hidaka T Kekkaku; 1993 Oct; 68(10):631-5. PubMed ID: 8255070 [TBL] [Abstract][Full Text] [Related]
12. [Effects of half-sized secretory leukocyte protease inhibitor and Chinese traditional medicines, yokuinin and mao-bushi-saishin-to, on therapeutic efficacies of benzoxazinorifamycin KRM-1648 against Mycobacterium avium complex infection induced in mice]. Sato K; Shimizu T; Tomioka H; Kawahara S Kekkaku; 1998 Aug; 73(8):501-6. PubMed ID: 9780605 [TBL] [Abstract][Full Text] [Related]
13. [Therapeutic efficacy of a benzoxazinorifamycin, KRM-1648, in Mycobacterium intracellulare infection induced in mice]. Saito H; Tomioka H; Sato K; Hidaka T Kekkaku; 1994 Feb; 69(2):59-63. PubMed ID: 8126989 [TBL] [Abstract][Full Text] [Related]
14. Evaluation of rifalazil in a combination treatment regimen as an alternative to isoniazid-rifampin therapy in a mouse tuberculosis model. Lenaerts AM; Chase SE; Cynamon MH Antimicrob Agents Chemother; 2000 Nov; 44(11):3167-8. PubMed ID: 11036043 [TBL] [Abstract][Full Text] [Related]
15. [Therapeutic effects of benzoxazinorifamycin KRM-1648 administered alone or in combination with glycyrrhizin against Mycobacterium avium complex infection in mice]. Shimizu T; Tomioka H; Sato K; Akaki T; Ogasawara K; Kawahara S Kekkaku; 1999 Aug; 74(8):617-21. PubMed ID: 10487030 [TBL] [Abstract][Full Text] [Related]
16. [In vitro activities of benzoxazinorifamycin KRM-1648 against Mycobacterium tuberculosis]. Sato K; Tomioka H; Saito H; Kawahara S; Hidaka T Kekkaku; 1996 Aug; 71(8):459-64. PubMed ID: 8831191 [TBL] [Abstract][Full Text] [Related]
17. How effective is KRM-1648 in treatment of disseminated Mycobacterium avium complex infections in beige mice? Ji B; Lounis N; Truffot-Pernot C; Grosset J Antimicrob Agents Chemother; 1996 Feb; 40(2):437-42. PubMed ID: 8834894 [TBL] [Abstract][Full Text] [Related]
18. [Therapeutic efficacy of a benzoxazinorifamycin, KRM-1648, combined with a immunopotentiator, LC9018, in Mycobacterium intracellulare infection induced in beige mice]. Tomioka H; Sato K; Saito H; Hidaka T Kekkaku; 1993 Dec; 68(12):751-4. PubMed ID: 8301917 [TBL] [Abstract][Full Text] [Related]
19. Activity of levofloxacin in a murine model of tuberculosis. Klemens SP; Sharpe CA; Rogge MC; Cynamon MH Antimicrob Agents Chemother; 1994 Jul; 38(7):1476-9. PubMed ID: 7979275 [TBL] [Abstract][Full Text] [Related]
20. Evaluation of rifapentine in long-term treatment regimens for tuberculosis in mice. Lenaerts AM; Chase SE; Chmielewski AJ; Cynamon MH Antimicrob Agents Chemother; 1999 Oct; 43(10):2356-60. PubMed ID: 10508006 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]